PT003 MDI

DRUG2 trials

Sponsors

Pearl Therapeutics, Inc.

Conditions

Chronic Obstructive Pulmonary Disease

Phase 2

Study to Evaluate the Efficacy, Safety and Pharmacokinetics of PT001, PT003, and PT005 Following Chronic Dosing (7 Days) in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)

CompletedNCT01085045

Pearl Therapeutics, Inc.Chronic Obstructive Pulmonary Disease

Start: 2010-03-31End: 2010-11-30Updated: 2017-04-26

PT003 MDI Cardiovascular Safety Study

CompletedNCT01349803

Pearl Therapeutics, Inc.Chronic Obstructive Pulmonary Disease

Start: 2011-05-31End: 2011-11-30Updated: 2017-01-31

Related Papers

A randomized, seven-day study to assess the efficacy and safety of a glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler using novel Co-Suspension™ Delivery Technology in patients with moderate-to-very severe chronic obstructive pulmonary disease

UNC Libraries2020-04-22

Randomized, double-blind, placebo-controlled trial to assess the efficacy and safety of three doses of co-suspension delivery technology glycopyrronium MDI in Japanese patients with moderate-to-severe COPD.

2018-04-136 citations

Cardiovascular safety profile of a fixed-dose combination of glycopyrrolate and formoterol fumarate delivered via metered dose inhaler using co-suspension delivery technology.

2018-02-046 citations

A randomized, seven-day study to assess the efficacy and safety of a glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler using novel Co-Suspension™ Delivery Technology in patients with moderate-to-very severe chronic obstructive pulmonary disease

Respiratory Research2017-01-0624 citations

Dose-response to inhaled glycopyrrolate delivered with a novel Co-Suspension™ Delivery Technology metered dose inhaler (MDI) in patients with moderate-to-severe COPD.

2016-09-0212 citations